What caused CLDX's Q2 earnings to beat forecasts?

Celldex Therapeutics' Q2 earnings did not beat forecasts, as the company actually reported a net loss of $47.09 million for the quarter. Therefore, it did not meet the expectations of analysts. The company's stock also entered oversold territory, indicating significant selling pressure and potential market pessimism.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|CLDX|CLDX.O|Celldex Therapeutics|2024 Q1|-11.740063349340963|-3.2808E7|186|
|CLDX|CLDX.O|Celldex Therapeutics|2024 Q2|-17.507048718116845|-3.5842E7|186|
|CLDX|CLDX.O|Celldex Therapeutics|2024 Q3|-10.09147935180345|-4.2121E7|186|
|CLDX|CLDX.O|Celldex Therapeutics|2024 Q4|-8.742437537523669|-4.7092E7|186|